{"product_id":"cbl514-20mg","title":"CBL514 20mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eCBL-514 — Investigational Injectable for Targeted Fat Reduction\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFirst-in-Class Small-Molecule Drug Candidate | Adipocyte Apoptosis | Localized Adipose Tissue Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCBL-514 is a first-in-class investigational injectable small-molecule drug candidate developed by Caliway Biopharmaceuticals for the targeted reduction of localized subcutaneous fat.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnlike conventional weight-management strategies, such as dietary modification, physical exercise, or incretin-based medications including semaglutide and tirzepatide, CBL-514 is designed to act directly on adipose tissue by inducing \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eadipocyte apoptosis — the programmed death of fat cells\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis targeted mechanism represents a distinct experimental approach to localized fat reduction, with potential applications in non-surgical body contouring and adipose tissue research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is administered through localized subcutaneous injections under investigational clinical protocols. Its clinical effectiveness, tissue selectivity, durability of response, and long-term safety remain under evaluation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is being developed to induce programmed cell death in targeted adipocytes, potentially reducing localized fat tissue volume.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts proposed mechanism involves three principal areas of investigation:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdipocyte Apoptosis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CBL-514 is designed to activate biological processes associated with programmed fat cell death. The precise contribution of individual molecular pathways continues to be evaluated through scientific research.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTargeted Subcutaneous Fat Reduction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e By inducing apoptosis in adipocytes within the treated region, CBL-514 aims to reduce localized subcutaneous fat volume. However, the elimination of targeted fat cells does not guarantee permanent cosmetic results, as remaining adipocytes may enlarge and adipose tissue can accumulate again.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTissue Selectivity and Local Tolerability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Available preclinical and clinical findings suggest potentially favorable local tolerability under studied conditions. Further investigation is required to fully characterize tissue selectivity, systemic exposure, rare adverse events, and long-term safety.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch Focus:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CBL-514 is being investigated as a localized adipose tissue intervention rather than a conventional appetite-suppressing or systemic weight-loss medication.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Trial Findings\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 has been evaluated in clinical trials investigating non-surgical subcutaneous fat reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch findings reported in connection with the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting included the following results.\u003c\/span\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003cspan\u003eResearch Parameter\u003c\/span\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cspan\u003eReported Clinical Findings\u003c\/span\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eSubcutaneous Fat Reduction\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eIn a Phase 2 study, 69.6% of CBL-514-treated participants achieved a reduction of at least 150 mL of subcutaneous fat in the treated area at the eight-week assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003ePlacebo Comparison\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eNo participants in the placebo group achieved the same reduction threshold at the eight-week assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat — Initial Follow-Up\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eIn an MRI-assessed subgroup of Phase 2 trial participants, mean visceral adipose tissue volume decreased by 12.01% from baseline.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat — Subsequent Follow-Up\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eMean visceral adipose tissue volume remained 10.45% below baseline at the later assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat — Placebo Group\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eMean visceral adipose tissue volume increased by 5.68% at the initial follow-up and by 11.76% at the subsequent assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eClinical Interpretation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese reported findings suggest that CBL-514 may have measurable effects on adipose tissue volume in selected clinical trial populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, the visceral fat results were derived from a subgroup of participants with available MRI measurements. They should therefore be considered \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003epreliminary clinical findings rather than definitive evidence of efficacy\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eLarger controlled studies are necessary to establish the reproducibility, clinical relevance, durability, and safety of these observations.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Clinical Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is being investigated across several areas of adipose tissue biology and therapeutic development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e1. Localized Subcutaneous Fat Reduction\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInvestigation of CBL-514 as a non-surgical approach to reducing localized subcutaneous fat deposits, particularly in abdominal regions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough potentially relevant to aesthetic medicine, CBL-514 has not been established or approved as an alternative to liposuction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e2. Visceral Adipose Tissue Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExploration of whether CBL-514 may influence visceral adipose tissue volume.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePreliminary MRI findings have generated scientific interest, but additional controlled studies are required to confirm these observations and determine their clinical significance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e3. Combination Research with Incretin-Based Therapies\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePreclinical investigations have explored the combination of CBL-514 with tirzepatide, a dual GIP\/GLP-1 receptor agonist.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAnimal research has suggested potential effects on weight reduction and weight regain following treatment discontinuation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA Phase 2 clinical development program is investigating this combination. The proposed benefits have not yet been established in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e4. Cellulite and Other Adipose Tissue Conditions\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch programs have also explored CBL-514 for additional adipose tissue-related indications, including cellulite.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA separate formulation, \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eCBL-514D\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, is under investigation for Dercum's disease, a rare disorder associated with painful fatty tissue deposits and lipomas.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese programs represent investigational applications and do not imply regulatory approval or established therapeutic effectiveness.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Development \u0026amp; Regulatory Status\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAs of October 2026, \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eCBL-514 remained an investigational pharmaceutical candidate without regulatory approval for routine clinical use or commercial distribution as an approved medicine\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts global Phase 3 development program includes the \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eSUPREME-01 clinical trial\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, designed to evaluate the efficacy and safety of CBL-514 for non-surgical reduction of abdominal subcutaneous fat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRegulatory authorization will depend on the results of clinical development, comprehensive safety assessments, and review by the relevant regulatory authorities.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eSafety \u0026amp; Tolerability\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eClinical studies reported to date have generally described CBL-514 as tolerable within the specific populations and treatment conditions evaluated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe most frequently reported adverse events have included temporary, mild-to-moderate injection-site reactions, such as:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eLocalized pain or discomfort\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eSwelling at the injection site\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eRedness and temporary skin reactions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese findings do not establish the absence of serious adverse events or confirm long-term safety.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant Safety Considerations\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInvestigational Status:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CBL-514 has not been approved for routine therapeutic or aesthetic use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIncomplete Long-Term Safety Data:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Potential delayed adverse effects and long-term tissue responses remain under investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eUncertain Durability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Permanent elimination of localized fat deposits has not been clinically established.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLimited Generalizability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Clinical trial results may not apply to populations outside those studied.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdministration-Related Risks:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Injection procedures may involve additional risks that require evaluation and appropriate clinical oversight.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 should not be represented as an approved weight-loss medication, a proven substitute for liposuction, or a treatment capable of guaranteeing permanent localized fat reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eScientific Research \u0026amp; Development Perspective\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 represents an emerging investigational approach in adipose tissue pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy focusing on adipocyte apoptosis rather than appetite regulation or caloric intake, the compound introduces a different strategy for exploring localized fat reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough early clinical findings are encouraging, \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eits therapeutic potential remains dependent on successful clinical development, confirmation of meaningful clinical benefits, and comprehensive safety evaluation\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR AUTHORIZED SCIENTIFIC AND CLINICAL RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is an investigational pharmaceutical compound intended for use exclusively within legitimate scientific research and appropriately authorized clinical investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot approved for general human or veterinary use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot intended for personal injection or self-administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot intended for unsupervised aesthetic or weight-loss procedures.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot authorized for routine clinical treatment or commercial therapeutic use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot established as safe or effective for diagnosing, treating, curing, or preventing any disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eThe designation “Research Use Only” does not replace applicable pharmaceutical regulations, clinical trial authorization requirements, or legal restrictions governing investigational medicines.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan\u003eScientific information provided for educational and research purposes. Clinical findings are preliminary and should be interpreted in the context of their original study designs, patient populations, and published evidence.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59501892665608,"sku":null,"price":200.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660","url":"https:\/\/peptgrind.com\/products\/cbl514-20mg","provider":"peptitan","version":"1.0","type":"link"}